Ocular Therapeutix, Inc.
NASDAQ:OCULBiotechnology
-$0.11 today
- Market cap
- $1.31B
- Beta
- 0.90
- P/E (TTM)
- -7.3
- EPS (TTM)
- -$1.30
Volume 3.67M
Average 3.00M
OCUL Capital Expenditures
Cash spent on property, plant, equipment, and other long-term assets.
Ocular Therapeutix, Inc.NASDAQ: OCUL
Capital Expenditures · Q1 FY2026 · quarter ended Mar 2026
Capital expenditures grows, but more slowly than its trailing trend
Q1 FY2026 capital expenditures of $4.66M (cash outflow) rose 141.2% year over year, behind the +396.9% change in trailing-twelve-month capital expenditures. Sequentially, it rose 64.2% from the prior quarter. Over 3 fiscal years it compounded at +47.9% a year.
Context
- Capital expenditures amounted to 23.2% of revenue in FY2025, up 21.2 pp from a year earlier.
- Capital expenditures grew in size in 2 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +141.2% toward the trailing-twelve-month pace of +396.9%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Capital Expenditures history
USD · from the cash flow
- Latest · FY2025
- (12.01M) USD
- Year-over-year change
- -832.5%
| Period | Period end | Capital Expenditures | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (12.01M) | -832.5% |
| FY2024 | 2024-12-31 | (1.29M) | +78.8% |
| FY2023 | 2023-12-31 | (6.09M) | -63.8% |
| FY2022 | 2022-12-31 | (3.72M) | -211.1% |
| FY2021 | 2021-12-31 | (1.19M) | — |
Capital Expenditures vs competitors
How OCUL compares with its peers on the latest reported figures
- Peers report in different currencies, so capital expenditures is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +396.9% is the 2nd highest of 9, against a peer median of +9.1%.
- Capital expenditures amounts to 28.3% of revenue for OCUL, versus a peer median of 2.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $318.06M USD | -9.4% | +25.9% | 6.0% | |
| LTM Mar 2026 | $14.74M USD | +396.9% | +47.9% | 28.3% | |
| LTM Jun 2026 | $11.25M USD | +78.5% | -36.7% | 1.8% | |
| LTM Apr 2026 | $4.8M USD | +140.8% | -31.5% | 1.7% | |
| LTM Mar 2026 | $4M USD | +27.7% | +15.1% | 52.5% | |
| LTM Sep 2026 | $3.32M USD | +465.1% | -78.0% | — | |
| LTM Mar 2026 | $926K USD | -97.6% | -47.9% | 0.3% | |
SGPSpyGlass Pharma, Inc. Common Stock | FY2025 | $789K USD | — | — | — |
| LTM Mar 2026 | CHF 294.17K CHF | -77.9% | -56.7% | 58.4% | |
| LTM Mar 2026 | $175K USD | -83.3% | -65.4% | 3.9% | |
| LTM Mar 2026 | $0 USD | — | — | 0.0% | |
| Peer median (excluding OCUL) | — | +9.1% | -42.3% | 2.9% | |
Competitors are the stored peer set for OCUL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (6.55M) | (71.04M) | (80.74M) | (193.51M) | (265.94M) |
| Depreciation & Amortization | 2.42M | 2.11M | 2.98M | 3.79M | 4.32M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 14.98M | 16.96M | 17.83M | 33.11M | 43.18M |
| Change in Working Capital | (2.9M) | 1.35M | (7.41M) | (10.23M) | 7.71M |
| Accounts Receivables | (8.88M) | (190K) | (4.85M) | (6.21M) | 1.74M |
| Inventory | (49K) | (724K) | (331K) | (735K) | (524K) |
| Accounts Payables | 1.8M | (621K) | 583K | (318K) | (887K) |
| Other Working Capital | 4.24M | 2.88M | (2.81M) | (2.97M) | 7.38M |
| Other Non-Cash Items | (73.49M) | (8.99M) | (2.9M) | 32.16M | 5.84M |
| Operating Cash Flow | (65.55M) | (59.6M) | (70.23M) | (134.68M) | (204.88M) |
| Capital Expenditures | (1.19M) | (3.72M) | (6.09M) | (1.29M) | (12.01M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 130K |
| Investing Cash Flow | (1.19M) | (3.72M) | (6.09M) | (1.29M) | (11.88M) |
| Debt Repayment | (445K) | 0 | 56.35M | 316.35M | 0 |
| Common Stock Issued | 985K | 940K | 118.11M | 316.35M | 561.72M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 2.31M | 514K | (4.63M) | (300.6M) | 0 |
| Financing Cash Flow | 2.85M | 1.45M | 169.83M | 332.11M | 561.72M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (63.89M) | (61.86M) | 93.51M | 196.15M | 344.96M |
| Free Cash Flow | (66.74M) | (63.32M) | (76.32M) | (135.97M) | (216.89M) |
Ocular Therapeutix, Inc.
NASDAQ:OCUL
Intrinsic Alpha fair value
Locked
Current Price
$5.94
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.